Cytel Podcasts

Regulatory Perspective of Trial Design Innovations in Rare Disease Development

Ursula Garczarek, Cytel Strategic Consulting

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 20:46

In our two-part interview, Cytel consulting statistician Ursula Garczarek reveals how rare disease development is benefitting from adaptive trial approaches.  In this episode, Ursula shares her insights on current international regulatory perspectives.  Ursula draws from he own considerable experiences, including defending adaptive trial statistical methodologies and their performance before EMA and FDA regulators.